Publication Results

Generate Report

Add publications by marking their checkboxes, or

Thyroid Incidentalomas in Association With Low-Dose Computed Tomography in the National Lung Screening Trial.

Loomans-Kropp HA,  Dunn BK,  Kramer BS,  Pinsky P
Am J Epidemiol 2020 Jan 31;189(1):27-33
Major Program(s) or Research Group(s): BiometryCancer Prevention Fellowship ProgramEarly Detection
PubMed ID: 31595954
PMC ID: not available

Editorial: Using Cancer 'Omics' to Understand Cancer.

Dunn BK,  Meerzaman D
Front Oncol 2020;10:1201
Major Program(s) or Research Group(s): Biometry
PubMed ID: 32850349
PMC ID: PMC7396572

Humanizing Big Data: Recognizing the Human Aspect of Big Data.

Helzlsouer K,  Meerzaman D,  Taplin S,  Dunn BK
Front Oncol 2020;10:186
Major Program(s) or Research Group(s): Biometry
PubMed ID: 32231993
PMC ID: PMC7082327

Value of Collaboration among Multi-Domain Experts in Analysis of High-Throughput Genomics Data.

Meerzaman D,  Dunn BK
Cancer Res 2019 Oct 15;79(20):5140-5145
Major Program(s) or Research Group(s): Biometry
PubMed ID: 31337654
PMC ID: PMC6801074

The Many Faces of Obesity and Its Influence on Breast Cancer Risk.

Agurs-Collins T,  Ross SA,  Dunn BK
Front Oncol 2019;9:765
Major Program(s) or Research Group(s): BiometryNutritional Science
PubMed ID: 31555578
PMC ID: PMC6737012

A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.

Gucalp A,  Zhou XK,  Cook ED,  Garber JE,  Crew KD,  Nangia JR,  Bhardwaj P,  Giri DD,  Elemento O,  Verma A,  Wang H,  Lee JJ,  Vornik LA,  Mays C,  Weber D,  Sepeda V,  O'Kane H,  Krasne M,  Williams S,  Morris PG,  Heckman-Stoddard BM,  Dunn BK,  Hudis CA,  Brown PH,  Dannenberg AJ
Cancer Prev Res (Phila) 2018 Apr;11(4):203-214
Major Program(s) or Research Group(s): Breast and Gynecologic CancerBiometry
PubMed ID: 29453232
PMC ID: PMC6290902

Incidental renal tumours on low-dose CT lung cancer screening exams.

Pinsky PF,  Dunn B,  Gierada D,  Nath PH,  Munden R,  Berland L,  Kramer BS
J Med Screen 2017 Jun;24(2):104-109
Major Program(s) or Research Group(s): BiometryEarly Detection ;  Office of the Director
PubMed ID: 28482765
PMC ID: not available

Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box.

Lazzeroni M,  Dunn BK,  Pruneri G,  Jereczek-Fossa BA,  Orecchia R,  Bonanni B,  DeCensi A
Cancer Treat Rev 2017 Apr;55:1-9
Major Program(s) or Research Group(s): Biometry
PubMed ID: 28262606
PMC ID: not available

Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women.

Provinciali N,  Suen C,  Dunn BK,  DeCensi A
Expert Rev Clin Pharmacol 2016 Oct;9(10):1263-1272
Major Program(s) or Research Group(s): BiometryProstate and Urologic Cancer
PubMed ID: 27583816
PMC ID: not available

Introduction: Cancer chemoprevention and its context.

Dunn BK,  Umar A,  Richmond E
Semin Oncol 2016 Feb;43(1):19-21
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentGastrointestinal and Other Cancers
PubMed ID: 26970121
PMC ID: PMC5166611

Repurposing old drugs to chemoprevention: the case of metformin.

Heckman-Stoddard BM,  Gandini S,  Puntoni M,  Dunn BK,  DeCensi A,  Szabo E
Semin Oncol 2016 Feb;43(1):123-133
Major Program(s) or Research Group(s): Breast and Gynecologic CancerChemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer
PubMed ID: 26970131
PMC ID: PMC4789107

The promise of omics-based approaches to cancer prevention.

Meerzaman D,  Dunn BK,  Lee M,  Chen Q,  Yan C,  Ross S
Semin Oncol 2016 Feb;43(1):36-48
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentNutritional Science
PubMed ID: 26970123
PMC ID: not available

Immunologic approaches to cancer prevention-current status, challenges, and future perspectives.

Wojtowicz ME,  Dunn BK,  Umar A
Semin Oncol 2016 Feb;43(1):161-172
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentGastrointestinal and Other CancersLung and Upper Aerodigestive Cancer
PubMed ID: 26970135
PMC ID: not available

Testing the Ability of Selenium and Vitamin E to Prevent Prostate Cancer in a Large Randomized Phase III Clinical Trial: The Selenium and Vitamin E Cancer Prevention Trial

Dunn BK,  Richmond E,  Anderson DE,  Greenwald P
2016
Malavoltaa M,  Mocchegiani E
Molecular Basis of Nutrition and Aging
A Volume in the Molecular Nutrition Series
ISBN: 978-0-12-801827-9; 978-0-12-801816-3
Major Program(s) or Research Group(s): BiometryGastrointestinal and Other CancersNutritional Science
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Cancer

Trujillo E,  Dunn BK,  Greenwald PG
2016
Mechanick JI,  Kushner RF
Lifestyle Medicine: A Manual for Clinical Practice
ISBN: 978-3-319-24685-7, 978-3-319-24687-1
Major Program(s) or Research Group(s): Nutritional Science

Predictive Value Tools as an Aid in Chemopreventive Agent Development.

Dunn BK,  Steele VE,  Fagerstrom RM,  Topp CF,  Ransohoff D,  Cunningham C,  Lubet R,  Ford LG,  Kramer BS
J Natl Cancer Inst 2015 Dec;107(12):djv259
Major Program(s) or Research Group(s): BiometryChemopreventive Agent Development ;  Office of the Director
PubMed ID: 26420882
PMC ID: PMC4862414

Legislation in the genomic era: the Affordable Care Act and genetic testing for cancer risk assessment.

Walcott FL,  Dunn BK
Genet Med 2015 Dec;17(12):962-4
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 25741860
PMC ID: not available

Metformin: risk-benefit profile with a focus on cancer.

Provinciali N,  Lazzeroni M,  Cazzaniga M,  Gorlero F,  Dunn BK,  DeCensi A
Expert Opin Drug Saf 2015 Oct;14(10):1573-85
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 26359221
PMC ID: not available

Chemoprevention of mammary cancer: Modeling predictive values of short-term morphologic assays for efficacy in animal tumor assays

Dunn Barbara K.,  Steele Vernon E.,  Fagerstrom Richard M.,  Topp Carol F.,  Kramer Barnett S.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 2813
Major Program(s) or Research Group(s): BiometryChemopreventive Agent Development ;  Office of the Director
PubMed ID: not available
PMC ID: not available

Vasomotor symptoms, BMI, and adherence to tamoxifen in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (P-1)

Walcott Farzana L.,  Land Stephanie R.,  Costantino Joseph P.,  Midthune Doug,  Dunn Barbara Karen
J Clin Oncol 2015 May 20;33(15):Abstract 1501
Major Program(s) or Research Group(s): BiometryChemopreventive Agent Development
PubMed ID: not available
PMC ID: not available

Understanding predictive values of short-term morphologic assays of cancer chemoprevention for efficacy in animal mammary gland tumor assays

Dunn Barbara K.,  Steele Vernon E.,  Topp Carol F.,  Fagerstrom Richard M.,  Kramer Barnett S.
Cancer Res 2015 May 1;75(9 Suppl):Abstract P5-06
Major Program(s) or Research Group(s): BiometryChemopreventive Agent Development ;  Office of the Director
PubMed ID: not available
PMC ID: not available

JNCI and cancer prevention.

Dunn BK,  Ghosh S,  Kramer BS
J Natl Cancer Inst 2015 Mar;107(3)
Major Program(s) or Research Group(s): Chemopreventive Agent Development ;  Office of the Director
PubMed ID: 25713150
PMC ID: PMC4351357

The Selenium and Vitamin E Cancer Prevention Trial (SELECT): Prevention of Prostate Cancer Using Selenium and/or Vitamin E in the SELECT Cancer Prevention Trial

Nicastro HL,  Dunn BK
2015
Preedy VR
Selenium: Chemistry, Analysis, Function and Effects
ISBN: 978-1-78262-221-5; 978-1-84973-891-0
Major Program(s) or Research Group(s): Biometry
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.

Gandini S,  Puntoni M,  Heckman-Stoddard BM,  Dunn BK,  Ford L,  DeCensi A,  Szabo E
Cancer Prev Res (Phila) 2014 Sep;7(9):867-85
Major Program(s) or Research Group(s): Breast and Gynecologic CancerChemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer
PubMed ID: 24985407
PMC ID: PMC4154969

A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.

Lee O,  Page K,  Ivancic D,  Helenowski I,  Parini V,  Sullivan ME,  Margenthaler JA,  Chatterton RT Jr,  Jovanovic B,  Dunn BK,  Heckman-Stoddard BM,  Foster K,  Muzzio M,  Shklovskaya J,  Skripkauskas S,  Kulesza P,  Green D,  Hansen NM,  Bethke KP,  Jeruss JS,  Bergan R,  Khan SA
Clin Cancer Res 2014 Jul 15;20(14):3672-82
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentPhase 0/I/II Cancer Prevention Clinical Trials Program
PubMed ID: 25028506
PMC ID: PMC4101910

A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease.

Gucalp A,  Morris PG,  Zhou XK,  Giri DD,  Iyengar NM,  Crew KD,  Hershman DL,  Garber JE,  Nangia JR,  Cook ED,  Vornik LA,  Heckman-Stoddard BM,  Dunn BK,  Foster K,  Brown PH,  Dannenberg AJ,  Hudis CA
J Clin Oncol 2014 May 20;32(15, Suppl S):Abstract TPS1615
Major Program(s) or Research Group(s): Phase 0/I/II Cancer Prevention Clinical Trials Program
PubMed ID: not available
PMC ID: not available

The Affordable Care Act and genetic testing for inheritable cancer syndromes: impact on high-risk underserved minorities.

Walcott FL,  Dunn BK,  DeShields M,  Baquet C
J Health Care Poor Underserved 2014 Feb;25(1 Suppl):46-62
Major Program(s) or Research Group(s): Cancer Prevention Fellowship ProgramChemopreventive Agent Development
PubMed ID: 24583487
PMC ID: not available

Genome-wide transcriptional sequencing identifies novel mutations in metabolic genes in human hepatocellular carcinoma.

Meerzaman DM,  Yan C,  Chen QR,  Edmonson MN,  Schaefer CF,  Clifford RJ,  Dunn BK,  Dong L,  Finney RP,  Cultraro CM,  Hu Y,  Yang Z,  Nguyen CV,  Kelley JM,  Cai S,  Zhang H,  Zhang J,  Wilson R,  Messmer L,  Chung YH,  Kim JA,  Park NH,  Lyu MS,  Song IH,  Komatsoulis G,  Buetow KH
Cancer Genomics Proteomics 2014 Jan-Feb;11(1):1-12
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 24633315
PMC ID: not available

Using Systems Biology to Understand Cancer as an Evolutionary Process

Pepper JW,  Dunn BK,  Fagerstrom RM,  Gohagan JK,  Vydelingum NA
Journal of Evolutionary Medicine 2014;2:1-8
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentBiometryCancer Biomarkers
PubMed ID: not available
PMC ID: not available

Abstract OT3-3-01: A multicenter phase II study of docosahexaenoic acid (DHA) in triple negative breast cancer (TNBC) survivors.

Gucalp A,  Morris PG,  Zhou XK,  Giri DD,  Iyengar NM,  Heckman-Stoddard BM,  Dunn B,  Garber JE,  Crew KD,  Hershman DL,  Nangia JR,  Cook ED,  Brown PH,  Dannenberg AJ,  Hudis CA
Cancer Res 2013 Dec 15;73(24 Suppl):OT3-01
Major Program(s) or Research Group(s): Phase 0/I/II Cancer Prevention Clinical Trials Program
PubMed ID: not available
PMC ID: not available

The word "cancer": how language can corrupt thought.

Dunn BK,  Srivastava S,  Kramer BS
BMJ 2013 Sep 10;347:f5328
Major Program(s) or Research Group(s): Cancer Biomarkers
PubMed ID: 24022035
PMC ID: not available

Exemestane: one part of the chemopreventive spectrum for ER-positive breast cancer.

Dunn BK,  Cazzaniga M,  DeCensi A
Breast 2013 Jun;22(3):225-37
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 23535509
PMC ID: not available

Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT).

Nicastro HL,  Dunn BK
Nutrients 2013 Apr 3;5(4):1122-48
Major Program(s) or Research Group(s): Chemopreventive Agent Development ;  Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer
PubMed ID: 23552052
PMC ID: PMC3705339
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Agent-Based Models in Cancer Prevention Research.

Pepper JW,  Vydelingum NA,  Dunn BK,  Fagerstrom RM
2013
Kora AB
Advances in Computational Modeling Research
ISBN: 978-1-62618-065-9
Major Program(s) or Research Group(s): BiometryCancer BiomarkersChemopreventive Agent Development

Future directions in cancer prevention.

Umar A,  Dunn BK,  Greenwald P
Nat Rev Cancer 2012 Dec;12(12):835-48
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 23151603
PMC ID: not available

Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.

Lazzeroni M,  Serrano D,  Dunn BK,  Heckman-Stoddard BM,  Lee O,  Khan S,  Decensi A
Breast Cancer Res 2012 Oct 29;14(5):214
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentBreast and Gynecologic Cancer
PubMed ID: 23106852
PMC ID: PMC4053098

Biomarkers as surrogate endpoints in cancer trials.

Dunn BK,  Akpa E
Semin Oncol Nurs 2012 May;28(2):99-108
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 22542317
PMC ID: not available

Biomarkers as molecular targets of drug interventions.

Smith JJ,  Dunn BK
Semin Oncol Nurs 2012 May;28(2):109-15
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 22542318
PMC ID: not available

Introduction.

Smith JJ,  Dunn BK
Semin Oncol Nurs 2012 May;28(2):85-6
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 22542314
PMC ID: not available

Exemestane for breast cancer prevention: a critical shift?

Decensi A,  Dunn BK,  Puntoni M,  Gennari A,  Ford LG
Cancer Discov 2012 Jan;2(1):25-40
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 22585166
PMC ID: PMC3354700

Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Nyante SJ,  Black A,  Kreimer AR,  Duggan MA,  Carreon JD,  Kessel B,  Buys SS,  Ragard LR,  Johnson KA,  Dunn BK,  Lamerato L,  Commins JM,  Berg CD,  Sherman ME
Gynecol Oncol 2011 Mar;120(3):474-9
Major Program(s) or Research Group(s): Early DetectionProstate, Lung, Colorectal, and Ovarian Cancer Screening TrialChemopreventive Agent Development
PubMed ID: 21144559
PMC ID: PMC3040283

Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities.

Dunn BK,  Jegalian K,  Greenwald P
Recent Results Cancer Res 2011;188:21-47
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 21253787
PMC ID: not available

Dynamics of Cancer Prevention.

Smith JJ,  Dunn B,  Greenwald P
2011
Yarbro CH,  Frogge M,  Goodman M,  Groenwald S
Cancer Nursing: Principles and Practices
ISBN: 9780763763572
Major Program(s) or Research Group(s): Lung and Upper Aerodigestive Cancer

Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer.

Agurs-Collins T,  Dunn BK,  Browne D,  Johnson KA,  Lubet R
Semin Oncol 2010 Aug;37(4):384-401
Major Program(s) or Research Group(s): Breast and Gynecologic CancerChemopreventive Agent Development
PubMed ID: 20816508
PMC ID: not available

Breast cancer prevention trials: large and small trials.

Arun B,  Dunn BK,  Ford LG,  Ryan A
Semin Oncol 2010 Aug;37(4):367-83
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 20816507
PMC ID: not available

The application of genetics and genomics to cancer prevention.

Calzone K,  Wattendorf D,  Dunn BK
Semin Oncol 2010 Aug;37(4):407-18
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 20816510
PMC ID: not available

Cancer Prevention II: Introduction.

Dunn BK,  Greenwald P
Semin Oncol 2010 Aug;37(4):321-6
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 20816502
PMC ID: not available

Health disparities in breast cancer: biology meets socioeconomic status.

Dunn BK,  Agurs-Collins T,  Browne D,  Lubet R,  Johnson KA
Breast Cancer Res Treat 2010 Jun;121(2):281-92
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 20437200
PMC ID: not available

Cancer prevention I: introduction.

Dunn BK,  Greenwald P
Semin Oncol 2010 Jun;37(3):190-201
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 20709204
PMC ID: not available

Molecular markers for early detection.

Dunn BK,  Wagner PD,  Anderson D,  Greenwald P
Semin Oncol 2010 Jun;37(3):224-42
Major Program(s) or Research Group(s): Cancer BiomarkersChemopreventive Agent Development
PubMed ID: 20709207
PMC ID: not available

Influence of genetic background and tissue types on global DNA methylation patterns.

Yang HH,  Hu N,  Wang C,  Ding T,  Dunn BK,  Goldstein AM,  Taylor PR,  Lee MP
PLoS One 2010 Feb 23;5(2):e9355
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 20186319
PMC ID: PMC2826396

Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.

Kadota M,  Yang HH,  Gomez B,  Sato M,  Clifford RJ,  Meerzaman D,  Dunn BK,  Wakefield LM,  Lee MP
PLoS One 2010 Feb 15;5(2):e9201
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 20169162
PMC ID: PMC2821407

Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial.

Dunn BK,  Greene MH,  Kelley JM,  Costantino JP,  Clifford RJ,  Hu Y,  Tang G,  Kazerouni N,  Rosenberg PS,  Meerzaman DM,  Buetow KH
Int J Mol Epidemiol Genet 2010;1(4):332-49
Major Program(s) or Research Group(s): Community Oncology and Prevention TrialsNCI Community Oncology Research ProgramChemopreventive Agent Development
PubMed ID: 21152245
PMC ID: PMC2998292
Clinical Trials: Breast Cancer Prevention Trial (BCPT)

A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Dunn BK,  Richmond ES,  Minasian LM,  Ryan AM,  Ford LG
Nutr Cancer 2010;62(7):896-918
Major Program(s) or Research Group(s): Gastrointestinal and Other CancersChemopreventive Agent Development ;  Community Clinical Oncology Program ;  Prostate and Urologic CancerCommunity Oncology and Prevention Trials
PubMed ID: 20924966
PMC ID: not available
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.

Kadota M,  Sato M,  Duncan B,  Ooshima A,  Yang HH,  Diaz-Meyer N,  Gere S,  Kageyama S,  Fukuoka J,  Nagata T,  Tsukada K,  Dunn BK,  Wakefield LM,  Lee MP
Cancer Res 2009 Sep 15;69(18):7357-65
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 19706770
PMC ID: PMC2745517

Landmarks in the history of cancer epidemiology.

Greenwald P,  Dunn BK
Cancer Res 2009 Mar 15;69(6):2151-62
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 19276341
PMC ID: not available

Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention.

Dunn BK,  Ryan A,  Ford LG
Recent Results Cancer Res 2009;181:183-93
Major Program(s) or Research Group(s): Chemopreventive Agent Development ;  Community Clinical Oncology Program ;  Community Oncology and Prevention TrialsProstate and Urologic Cancer
PubMed ID: 19213568
PMC ID: not available
Clinical Trials: Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Do we make optimal use of the potential of cancer prevention?

Greenwald P,  Dunn BK
Recent Results Cancer Res 2009;181:3-17
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 19213552
PMC ID: not available

Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery.

Demark-Wahnefried W,  Polascik TJ,  George SL,  Switzer BR,  Madden JF,  Ruffin MT 4th,  Snyder DC,  Owzar K,  Hars V,  Albala DM,  Walther PJ,  Robertson CN,  Moul JW,  Dunn BK,  Brenner D,  Minasian L,  Stella P,  Vollmer RT
Cancer Epidemiol Biomarkers Prev 2008 Dec;17(12):3577-87
Major Program(s) or Research Group(s): Chemopreventive Agent Development ;  Office of the Director
PubMed ID: 19064574
PMC ID: PMC2703189

Introduction: diet, epigenetic events and cancer prevention.

Ross SA,  Dwyer J,  Umar A,  Kagan J,  Verma M,  Van Bemmel DM,  Dunn BK
Nutr Rev 2008 Aug;66 Suppl 1:S1-6
Major Program(s) or Research Group(s): Gastrointestinal and Other Cancers
PubMed ID: 18673478
PMC ID: PMC2547124

Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.

Dunn BK,  Ford LG
Eur J Cancer Prev 2007 Jun;16(3):232-42
Major Program(s) or Research Group(s): Chemopreventive Agent Development ;  Office of the Director
PubMed ID: 17415094
PMC ID: not available

Association of energy intake and energy balance with postmenopausal breast cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

Chang SC,  Ziegler RG,  Dunn B,  Stolzenberg-Solomon R,  Lacey JV Jr,  Huang WY,  Schatzkin A,  Reding D,  Hoover RN,  Hartge P,  Leitzmann MF
Cancer Epidemiol Biomarkers Prev 2006 Feb;15(2):334-41
Major Program(s) or Research Group(s): Early DetectionProstate, Lung, Colorectal, and Ovarian Cancer Screening Trial
PubMed ID: 16492925
PMC ID: not available

Prevention of hormone-related cancers: breast cancer.

Dunn BK,  Wickerham DL,  Ford LG
J Clin Oncol 2005 Jan 10;23(2):357-67
Major Program(s) or Research Group(s): Chemopreventive Agent Development ;  Office of the Director
PubMed ID: 15637398
PMC ID: not available

Epigenetics in cancer prevention: early detection and risk assessment: introduction.

Dunn BK,  Verma M,  Umar A
Ann N Y Acad Sci 2003 Mar;983:1-4
Major Program(s) or Research Group(s): Gastrointestinal and Other Cancers
PubMed ID: 12724207
PMC ID: not available

Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention.

Verma M,  Dunn BK,  Ross S,  Jain P,  Wang W,  Hayes R,  Umar A
Ann N Y Acad Sci 2003 Mar;983:298-319
Major Program(s) or Research Group(s): Gastrointestinal and Other CancersCancer BiomarkersNutritional Science
PubMed ID: 12724234
PMC ID: not available

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

King MC,  Wieand S,  Hale K,  Lee M,  Walsh T,  Owens K,  Tait J,  Ford L,  Dunn BK,  Costantino J,  Wickerham L,  Wolmark N,  Fisher B,  National Surgical Adjuvant Breast and Bowel Project
JAMA 2001 Nov 14;286(18):2251-6
Major Program(s) or Research Group(s): Community Oncology and Prevention TrialsNCI Community Oncology Research Program ;  Community Clinical Oncology Program
PubMed ID: 11710890
PMC ID: not available
Clinical Trials: Breast Cancer Prevention Trial (BCPT)

Breast cancer prevention: the next steps.

Dunn BK,  McCaskill-Stevens W,  Ford LG
Eur J Cancer 2000 Sep;36 Suppl 4:S53-4
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentCommunity Oncology and Prevention Trials ;  Office of the Director
PubMed ID: 11056319
PMC ID: not available

Surrogate anatomic/functional sites for evaluating cancer risk: an extension of the field effect.

Kopelovich L,  Henson DE,  Gazdar AF,  Dunn B,  Srivastava S,  Kelloff GJ,  Greenwald P
Clin Cancer Res 1999 Dec;5(12):3899-905
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: 10632318
PMC ID: not available